Jeffrey Allen

Otto and Marguerite Manley and Making Headway Foundation Professor of Pediatric Neuro-Oncology and Professor (Clinical) of Neurology

NYU School of Medicine
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF , RAF , or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR , and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.

Year:

2024

DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF , RAF , or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR , and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.

Year:

2024

Collaborators (9)

Matija Snuderl

Assistant Professor (Clinical) of Pathology

NYU School of Medicine

UNITED STATES
View details

George Jour

Associate professor

NYU Langone Medical Center

UNITED STATES
View details

Jeffrey Wisoff

Professor of Neurosurgery and Pediatrics

NYU School of Medicine

UNITED STATES
View details

Tejus Bale

Assistant Attending L1

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Eveline Teresa Hidalgo

NYU Langone Health

UNITED STATES
View details

david harter

NYU Langone Medical Center

UNITED STATES
View details

Daniel Orringer

Associate Professor

NYU Langone Health

UNITED STATES
View details

Benjamin Liechty

Assistant Professor of Pathology and Laboratory Medicine

Weill Cornell Medicine

UNITED STATES
View details

Sharon L Gardner

Associate Professor (Clinical) of Pediatrics

NYU School of Medicine

UNITED STATES
View details